VaxartSTU:NB11 59 Interest Coverage is 10.24 as of Mar. 2026, which is 60% above its 10-year median of 6.40. GuruFocus rates STU:NB11 with a GF Score™ of 59/100 and a GF Value™ of €8.01. The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, Vaxart ranks worse than 70.03% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vaxart's
Operating Income
for the
three
months ended in Mar. 2026 was €4.5 Mil. Vaxart's Interest Expense for the
three
months ended in Mar. 2026 was €-0.4 Mil.
Vaxart's interest coverage for the quarter that ended in Mar. 2026 was 10.24.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Vaxart's Interest Coverage or its related term are showing as below:
STU:NB11'
s Interest Coverage Range Over the Past 10 Years
Min: 6.4 Med: 6.4 Max: 16.38
Current: 16.38
STU:NB11's Interest Coverage is ranked worse than 70.03% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs STU:NB11: 16.38
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vaxart Interest Coverage Related Terms
Vaxart Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vaxart's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:NB11 vs SPRO, ADCT, GNLX: Interest Coverage Comparison
For the Biotechnology subindustry, Vaxart's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxart Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxart's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vaxart's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxart (STU:NB11) has a Interest Coverage of 10.24 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vaxart and its competitors. This is 60% above median its historical median of 6.40. Over the past decade, Vaxart's Interest Coverage has ranged from 6.40 to 16.38. According to the industry distribution chart, Vaxart ranks #264 out of 377 companies in the Biotechnology industry, placing it in the top 70%.
Is Vaxart's Interest Coverage too high?
Vaxart's current Interest Coverage of 10.24 is 60% above median its 10-year median of 6.40. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 16.38. The Biotechnology industry median Interest Coverage is 106.07. Vaxart's value of 10.24 is 90.3% below this industry median. Based on the distribution chart, Vaxart ranks #264 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vaxart has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Interest Coverage compare to SPRO and ADCT?
According to the Biotechnology industry distribution chart, Vaxart ranks #264 out of 377 companies for Interest Coverage. This places Vaxart in the lower half of its industry. The industry median Interest Coverage is 106.07. Vaxart's value of 10.24 is 90.3% below this benchmark. Historically, Vaxart's own Interest Coverage has ranged from 6.40 to 16.38 over the past decade. While the company's 10-year median is 6.40 vs. the industry median of 106.07, Vaxart has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxart's current Interest Coverage of 10.24 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vaxart and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxart's current Interest Coverage is 10.24, which is 60% above median its own 10-year median of 6.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current Interest Coverage of 10.24. The stock's GF Value™ is €8.01, compared to a current price of €0.60 — trading 92.5% below its estimated fair value. The current Interest Coverage is 10.24, which is 60% above median its 10-year median of 6.40 and 90.3% below the Biotechnology industry median of 106.07. Vaxart's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vaxart (STU:NB11), the current Interest Coverage is 10.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaxart (STU:NB11) Overvalued in 2026?
Based on GuruFocus' analysis, Vaxart stock appears to be undervalued.
The current stock price of €0.60 is trading 92.5% below its estimated GF Value™ of €8.01.
Key valuation signals for STU:NB11:
Interest Coverage: 10.24 (60% above median its 10-year median of 6.40)
GF Value™: €8.01 vs. price of €0.60 (92.5% below fair value)
Industry Position: 90.3% below the Biotechnology median (#264 of 377)
No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
59GF Score
Get the complete analysis for STU:NB11
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NB11 has been successfully added to your 
